Vivoryon Therapeutics (VVY) Q2 2026 earnings summary

Executive summary

• Advanced term sheet negotiations are ongoing for a licensing agreement for varoglutamstat in kidney disease, with increased external interest and independent assessment by a specialist kidney-focused investor; updates are expected in the coming weeks.

• Varoglutamstat demonstrated significant and clinically meaningful improvements in kidney function, especially in diabetic patients with lower baseline eGFR, and has a differentiated mechanism targeting inflammation, fibrosis, and endothelial function.

• New clinical and mechanistic data were presented at major international kidney conferences, reinforcing efficacy and mechanism of action.

• Focus remains on addressing the significant unmet need in diabetic kidney disease, with a large patient population in the US and EU.

• The company maintains a cash runway into Q4 2026 and is actively exploring additional financing and partnership opportunities.

Financial highlights

• No revenue reported for H1 2026 or H1 2025.

• Research and development expenses decreased to EUR 1.7 million from EUR 2.8 million year-over-year.

• General and administrative expenses fell to EUR 1.7 million from EUR 2.8 million year-over-year.

• Net loss for H1 2026 narrowed to EUR 3.4 million from EUR 5.5 million year-over-year.

• Cash and cash equivalents stood at EUR 2.4 million as of June 30, 2026, down from EUR 5.6 million at year-end 2025.

Outlook and guidance

• Cash runway is expected to last into Q4 2026, excluding potential proceeds from a standby equity purchase agreement.

• Initiation of a dedicated Phase 2b study in advanced kidney disease is planned, pending successful partnership or financing.

• Future viability depends on securing additional funding or partnerships to advance clinical programs, with continued operating losses anticipated.